It's likely there was an improvement in mortality if it passed the interim readout at 45%, just not one that would pass the trial at the given powering.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-284
-
- There are more pages in this discussion • 792 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.010(0.90%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.12 | $1.09 | $379.2K | 343.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11651 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6044 | 4 |
View Market Depth
| Last trade - 10.07am 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |